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Abstract
Background: Previous studies have reported that microalbuminuria is an independent risk factor for the prevalence
of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (DM). For this reason, the clinical significance
of DR in normoalbuminuric type 2 DM patients may be overlooked. The aim of this study was to investigate the
prevalence of DR and predictors for DR in normoalbuminuric patients with type 2 DM.
Methods: A total 310 patients with type 2 DM and normoalbuminuria, who were referred to the Department of
Ophthalmology for screening of DR were included in this study. DR was clinically graded according to the
International Clinical Diabetic Retinopathy guidelines. The urinary albumin excretion rate (UAER) was assessed via
24-hour urine collection and measured by immunoturbidimetric assay. Normoalbuminuria was defined as a
UAER< 20 μg/min in 2 out of 3 consecutive tests taken within 2–3 months.
Results: DR of any grade was present in 64/310 (20.7 %) patients. Mild non-proliferative diabetic retinopathy (NPDR)
was most prevalent in patients with DR of any grade (36/64, 56 %). The duration of diabetes (OR 1.01, 95 % CI,
1.01 – 1.02, p< 0.001), hemoglobin levels (OR 0.73, 95 % CI, 0.59 – 0.91, p = 0.004) and a higher tertile of UAER
(OR 4.04, 95 % CI, 1.71 – 9.57, p = 0.001) had independently significant association with DR. NPDR as well as PDR
was more prevalent in patients with higher tertile of UAER compared with those with lower tertile of UAER (NPDR,
p = 0.002 and PDR, p = 0.027, respectively).
Conclusions: Our findings suggest that patients with normoalbuminuric type 2 DM also require close monitoring
for the early detection of DR, especially if they have a higher UAER, longer duration of diabetes, or lower
hemoglobin levels.
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Background
Diabetic retinopathy (DR) is one of the leading causes of
visual impairment and blindness in people with diabetes
mellitus (DM) [1-3]. As the prevalence of DM increases,
the development of DR as a microvascular complication
of DM also rises. Furthermore, previous studies demon-
strated that DR has also been associated with cardiovas-
cular and all cause mortality as well as visual morbidity
in patients with type 2 DM [4,5], which adds value to in-
vestigating the prevalence and risk factors for DR.
Microalbuminuria is a marker of endothelial dysfunc-
tion and may influence on alterations in the microvascu-
lature of retina and kidneys. Previous studies have
demonstrated that microalbuminuria is predictive for
certain diabetic complications such as diabetic nephro-
pathy, and is a useful marker for early detection and
treatment [6]. Regarding the association between micro-
albuminuria and DR, microalbuminuria has been
demonstrated to be an independent risk factor for the
incidence of DR in patients with type 1 DM [6-9]. How-
ever, in patients with type 2 DM, it is controversial
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whether microalbuminuria is independently associated
with the incidence of DR [6,10,11]. These findings sug-
gest that DR might develop in patients with type 2 DM
without microalbuminuria. Furthermore, previous stud-
ies reported that DR is prevalent in normoalbuminuric
patients with type 2 DM and its prevalence is ~10-30 %
[11-13]. However, there are few data concerning the
prevalence of DR according to the severity and predic-
tors for DR in normoalbuminuric patients with type 2
DM. Establishing the prevalence of DR according to the
severity and predictors for DR may be helpful for early
detection and treatment of DR in normoalbuminuric
patients with type 2 DM. Therefore, the purpose of this
study was to investigate the prevalence of DR according
to the severity and predictors for DR in normoalbumi-
nuric patients with type 2 DM.
Materials and methods
Study population
This was a retrospective cross-sectional study. The
present study included patients with type 2 DM and nor-
moalbuminuria, who were referred to the Department of
Ophthalmology for screening of DR and underwent a
dilated fundus examination and fundus photographic
evaluation at the Bucheon Saint Mary’s Hospital between
July 2005 and December 2007. Type 2 DM was diag-
nosed if the patients with a fasting plasma glucose level
≥126 mg/dl or a 2-h post-glucose level after a 75-g oral
glucose tolerance test ≥ 200 mg/dl [14]. Patients who
were treated by diet alone or in combination with
oral hypoglycemic agents or they had fasting serum
C-peptide values greater than 1.0 ng/mL when adminis-
tered insulin were also categorized as type 2 DM. Nor-
moalbuminuria was defined as a urinary albumin
excretion rate (UAER)< 20 μg/min in 2 out of 3 con-
secutive tests taken within 2–3 months [15]. The exclu-
sion criteria were 1) an age< 18 years or> 80 years, 2)
accelerated hypertension 3) pregnancy, 4) malignancies,
5) severely disabled patients such as hepatic failure or
heart failure, 6) schizophrenia, 7) goiter, and 8) acute sys-
temic infection. The study protocol was approved by the
local ethical committee, and this study was conducted
according to the principles of the Declaration of
Helsinki.
Ophthalmic examination and definition of
diabetic retinopathy
Each participant underwent a comprehensive ophthal-
mic examination that included automated refraction
(RK-F1, Canon), non-contact tonometry (TX-F, Canon),
lens grading at the slit lamp, and stereoscopic fundus
examination using an indirect ophthalmoscope, and a
slit lamp biomicroscope with a “superfield lens” (Volk,
Mentor, OH, USA) after pupil dilatation with 1.0 %
tropicamide and 10 % phenylephrine. Fundus photo-
graphs (45 °) were taken from both eyes of each partici-
pant using a digital fundus camera (VX-10i, Kowa,
Japan). The photographs were taken in 1-field per eye,
centered on the macula. Diagnosis of DR was made by a
trained ophthalmologist by an indirect ophthalmoscopic
examination based on the presence of clinical features in
the fundus of both eyes following the International Clin-
ical Diabetic Retinopathy guidelines, and classified as (i)
no apparent retinopathy, (ii) mild nonproliferative dia-
betic retinopathy (NPDR), (iii) moderate NPDR, (iv) se-
vere NPDR, or (iv) proliferative diabetic retinopathy
(PDR) [16].
Clinical information and laboratory analysis
Clinical information was assessed from the written and
electronic medical records, and this information
included the medical history, current medications and
laboratory data. The collected data included age, gender,
body mass index (BMI), systolic and diastolic blood
pressures, the duration of diabetes, serum creatinine,
hemoglobin and albumin levels, total cholesterol and
high-density lipoprotein (HDL) cholesterol levels, trigly-
ceride and serum uric acid levels, the UAER, the homeo-
stasis model for insulin resistance (HOMA-IR) score,
lipoprotein (a) and high-sensitivity C-reactive protein
(hs-CRP) levels. Drug histories in relation to anti-
hypertensive agents including renin-angiotensin system
(RAS) inhibitors were also evaluated. Fasting venous
blood samples were taken for the determination of the
serum level of total cholesterol, HDL cholesterol and tri-
glyceride. The UAER was assessed via 24 hour urine col-
lection and measured by immunoturbidimetric assay
using Roche/Hitachi MODULAR automated clinical
chemistry analyzers (Roche Diagnostic, GmbH, Mann-
heim, Germany). The BMI was calculated as weight
(kg)/height (m2). The blood pressure was measured
twice, 5 minutes apart, using a random zero sphygmo-
manometer with the patient seated after 10 minutes of
rest. The estimated GFR (eGFR) was calculated using
the Modification of Diet in Renal Disease four-variable
equation at the time of CT scanning: eGFR= 186xserum
creatinine-1.154xage-0.203x1.212 (if black)x0.742 (if female)
[17]. The HOMA-IR was calculated with the following
formula: [Fasting insulin (μIU/mL) × fasting plasma glu-
cose (mmol/L)]/22.5 [18].
Statistics
The data for continuous variables with a normal distri-
bution is expressed as means ± SDs and the data for the
continuous variables without a normal distribution is
expressed as medians with interquartile ranges. The Stu-
dent’s t-test or Mann–Whitney test were used, as appro-
priate, to determine differences in continuous variables.
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Categorical variables are presented as percentage. The
Pearson’s chi-square test or Fisher’s exact test, as appro-
priate, was used to determine the differences in categor-
ical variables. Both univariate and multivariate logistic
regression analyses were performed to determine the
various risk factors for the presence of DR. From the
univariate analysis, variables with p< 0.05 and those
which were already established as risk factors were
included in the multivariate logistic regression analysis.
These variables included age, gender, systolic blood
pressure, duration of DM, eGFR, hemoglobin, use of
RAS inhibitors and urinary albumin excretion rate.
P values< 0.05 were considered statistically significant.
The statistical analyses were performed using SPSS
15.0 software (Chicago, IL, USA).
Results
A total 310 patients were enrolled in this study. The
mean age of enrolled patients was 54 ± 14 years (median,
54 years; interquartile range, 46 – 65 years). This study
included 153 males (49.4 %) and 157 females (50.6 %).
Median duration of diabetes was 29 months (interquar-
tile range, 2 – 110 months) and the mean eGFR was
97 ± 25 ml/min/1.73 m2.
Table 1 shows the prevalence of DR according to the
diabetic retinopathy staging system presented by the
International Clinical Diabetic Retinopathy guidelines.
DR of any grade was present in 64/310 (20.7 %) patients.
Of the patients with DR of any grade, 54/64 (84.4 %)
had NPDR and 10/64 (15.6 %) had PDR. Of the patients
with NPDR, 36/54 (66.7 %) had mild NPDR, 5/54
(9.3 %) had moderate NPDR and 13/54 (24.1 %) had se-
vere NPDR, respectively.
Comparisons of clinical characteristics between the
patients with DR and without DR are shown in Table 2.
The patients with DR were older than those without DR
and DR was more prevalent in females than in males.
The patients with DR had lower BMI, higher systolic
blood pressure, longer duration of diabetes, lower eGFR,
lower hemoglobin levels, lower serum total cholesterol
levels and higher UAER compared with those without
DR. The number of patients using RAS inhibitors was
101 (32.6 %) and the patients with DR had higher preva-
lence of using RAS inhibitors compared with those with-
out DR. In univariate logistic regression analysis with
the presence of DR as dependent variable, age, gender,
BMI, systolic blood pressure, duration of diabetes, eGFR,
hemoglobin levels, use of RAS inhibitors and higher ter-
tile of UAER were significantly associated with the pres-
ence of DR (Table 3). Multivariate logistic regression
analysis to determine the predictor of DR in normolabu-
minuric people with type 2 DM are shown in Table 4.
Data revealed that the duration of diabetes (OR 1.01,
95 % CI, 1.01 – 1.02, p< 0.001), hemoglobin levels (OR
0.73, 95 % CI, 0.59 – 0.91, p = 0.004), and a higher tertile
of UAER (OR 4.04, 95 % CI, 1.71 – 9.57, p = 0.001) had
independently significant association with DR. As the
UAER was a strong predictor of the presence for DR, we
analyzed the prevalence of diabetic retinopathy accord-
ing to the tertiles of urinary albumin excretion rate
(Table 5). NPDR as well as PDR was more prevalent in
patients with a higher tertile of UAER compared with
Table 1 Prevalence of diabetic retinopathy according to
the diabetic retinopathy staging system presented by the
International Clinical Diabetic Retinopathy guidelines in
normoalbuminuric people with type 2 DM
Number of patients (n = 310)
No diabetic retinopathy 246 (79.4)
NPDR, mild 36 (11.6)
NPDR, moderate 5 (1.6)
NPDR, severe 13 (4.2)
PDR 10 (3.2)
Data are expressed as n (%).
Abbreviations: NPDR non-proliferative diabetic retinopathy, PDR proliferative
diabetic retinopathy.
Table 2 Comparisons of clinical characteristics between
the patients with DR and without DR
Clinical characteristics No DR (n = 246) DR (n = 64) P value
Age, years 53 ± 13 61 ± 12 < 0.001
Female, n (%) 114 (46.3) 43 (67.2) 0.003
BMI, kg/m2 25.0 ± 3.7 23.9 ± 3.0 0.022
Systolic blood pressure, mmHg 127 ± 14 132± 17 0.018
Diastolic blood pressure, mmHg 77 ± 10 77 ± 9 0.836
Duration of diabetes, months 17 (1–75) 117 (60–191) < 0.001
Serum creatinine, mg/dL 0.8 ± 0.2 0.8 ± 0.2 0.797
Estimated GFR, ml/min/1.73 m2 99 ± 25 89 ± 22 0.003
Hemoglobin, g/dL 13.9 ± 1.8 12.6 ± 1.7 < 0.001
Serum albumin, g/dL 4.4 ± 0.4 4.3 ± 0.4 0.111
Serum total cholesterol, mg/dL 187 ± 42 174± 44 0.049
Serum triglyceride, mg/dL 167 ± 119 181± 132 0.411
Serum HDL, mg/dL 51 ± 14 48 ± 17 0.076
Serum uric acid, mg/dL 4.3 ± 1.4 4.5 ± 1.6 0.550
Urinary albumin excretion,
μg/min
5.92 ± 3.50 8.97 ± 5.07 < 0.001
Hemoglobin A1c 9.2 ± 2.5 9.1 ± 1.9 0.741
HOMA-IR 3.4 ± 4.6 4.0 ± 4.3 0.347
Lipoprotein (a), (IU/L) 135 (46–341) 171 (42–387) 0.496
hs-CRP, mg/dL 0.2 (0.1-0.9) 0.2 (0.1-0.7) 0.854
Use of RAS inhibitors, n (%) 68 (27.6) 33 (51.6) < 0.001
Values are expressed as means ± SDs, medians (interquartile range) or n(%).
Abbreviations: DR diabetic retinopathy, BMI body mass index, GFR glomerular
filtration rate, HDL high-density lipoprotein, HOMA-IR homeostasis model for
insulin resistance, hs-CRP high-sensitivity C-reactive protein,
RAS renin-angiotensin system.
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those with a lower tertile of UAER (NPDR, p = 0.002 and
PDR, p = 0.027, respectively).
Discussion
In this study, we reported the prevalence of diabetic ret-
inopathy according to the severity and predictors for DR
in normoalbuminuric patients with type 2 DM. Previous
studies reported that microalbuminuria was independ-
ently associated with the prevalence of NPDR and PDR
in patients with type 2 DM [11,12,19-21]. For this rea-
son, the clinical significance of DR in normoalbuminuric
type 2 DM patients may be overlooked. Normoalbumi-
nuria is much more prevalent than microalbuminuria
and macroalbuminuria in patients with type 2 DM. The
prevalence of normoalbuminuria was reported to be 68
– 81 % in patients with type 2 DM in population-based
cross sectional studies [12,22,23]. In spite of the high
prevalence of normoalbuminuria in patients with type
2 DM, the prevalence of diabetic retinopathy according
to the severity and predictors for DR in normoalbumi-
nuric patients with type 2 DM has not been well
studied.
In our study, the prevalence of DR with any grade was
20.7 %, which is similar to the prevalence of DR as 10 –
30 % reported in previous studies on normoalbuminuric
patients with type 2 DM [11-13]. Our study also ana-
lyzed the prevalence of DR according to its severity.
NPDR was more prevalent than PDR, and mild NPDR
was most prevalent in patients with NPDR with any
grade. Our findings mean that DR is prevalent even in
normoalbuminuric patients with type 2 DM, and mild
NPDR is most the common form according to the DR
staging system presented by the International Clinical
Diabetic Retinopathy guidelines.
In our study, we showed that the duration of diabetes,
hemoglobin levels, and UAER were independent predic-
tors for the presence of DR in normoalbuminuric
patients with type 2 DM. Interestingly, the UAER was
the strongest predictor for the presence of DR in nor-
moalbuminuric patients with type 2 DM even after ad-
justment for age, gender, systolic blood pressure,
duration of DM, eGFR and use of RAS inhibitors. Previ-
ous studies have reported that microalbuminuria is asso-
ciated with the prevalence of DR in patients with type 2
DM [19-21]. Most of the previous studies included type
2 DM patients with not only normoalbuminuria, but
also microalbuminuria and macroalbuminuria. It has not
been well known whether the UAER could predict the
presence of DR even in normoalbuminuric patients with
Table 3 Univariate logistic regression analysis with
diabetic retinopathy as a dependent variable in
normolabuminuric people with type 2 DM
DR
Odds ratio 95 % CI P value
Age 1.05 1.03 – 1.08 < 0.001
Gender (female) 2.37 1.33 – 4.23 0.003
BMI 0.91 0.83 – 0.99 0.023
Systolic blood pressure 1.02 1.00 – 1.04 0.019
Diastolic blood pressure 1.00 0.98 – 1.03 0.835
Duration of diabetes 1.01 1.01 – 1.02 < 0.001
Serum creatinine 1.16 0.37 – 3.70 0.797
Estimated GFR 0.98 0.97 – 0.99 0.004
Hemoglobin 0.67 0.57 – 0.79 < 0.001
Serum albumin 0.57 0.29 – 1.14 0.573
Serum total cholesterol 0.99 0.99 - 1.00 0.050
Serum triglyceride 1.00 1.00 – 1.00 0.411
Serum HDL 0.98 0.96 – 1.00 0.077
Serum uric acid 1.06 0.88 – 1.28 0.549
Hemoglobin A1c 0.96 0.88 – 1.07 0.418
HOMA-IR 0.98 0.87 – 1.10 0.981
Lipoprotein (a) 1.0 1.0 – 1.0 0.876
hs-CRP 1.01 0.99 – 1.04 0.375
Use of RAS inhibitors 2.79 1.59 – 4.90 < 0.001
Urinary albumin excretion
rate tertiles
I (< 4.26 μg/min) 1 - -
II (4.26 -7.21 μg/min) 1.38 0.62 – 3.08 0.433
III (> 7.21 μg/min) 4.08 1.97 – 8.42 < 0.001
Abbreviations: DR diabetic retinopathy, BMI body mass index, GFR glomerular
filtration rate, HDL high-density lipoprotein, HOMA-IR homeostasis model for
insulin resistance, hs-CRP high-sensitivity C-reactive protein,
RAS renin-angiotensin system.
Table 4 Multivariate logistic regression analysis to
determine the predictor of diabetic retinopathy in
normolabuminuric people with type 2 DM
DR
Odds ratio 95 % CI P value
Age 1.00 0.97 – 1.04 0.872
Gender (female) 1.08 0.51 – 2.28 0.837
Systolic blood pressure 1.02 0.99 – 1.04 0.197
Duration of diabetes 1.01 1.01 – 1.02 < 0.001
Estimated GFR 1.00 0.99 – 1.02 0.985
Hemoglobin 0.73 0.59 – 0.91 0.004
Use of RAS inhibitors 1.83 0.92 – 3.62 0.084
Urinary albumin excretion
rate tertiles
I (< 4.26 μg/min) 1 - -
II (4.26 -7.21 μg/min) 1.34 0.52 – 3.44 0.543
III (> 7.21 μg/min) 4.04 1.71 – 9.57 0.001
Abbreviations: DR, diabetic retinopathy; GFR, glomerular filtration rate;
RAS, renin-angiotensin system.
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type 2 DM. To our knowledge, this study is the first to
investigate the association between UAER and the pres-
ence of DR in normoalbuminuric patients with type 2
DM. Furthermore, in our study, not only NPDR, but also
PDR, was more prevalent in patients with a higher tertile
of UAER compared with those with a lower tertile of
UAER, which means that UAER was associated with the
severity of DR in normoalbuminuric people with type 2
DM. Our findings suggest that even in patients with nor-
moalbuminuric type 2 DM, close monitoring for DR
might be needed for the early detection of DR if they
have a higher UAER.
In our study, a longer duration of diabetes and lower
hemoglobin levels were also independently associated
with the prevalence of DR. The duration of diabetes is a
well known predictor for the presence of DR in patients
with type 2 DM [12,21,24]. The duration of diabetes is
regarded as a marker for long-term exposure to hyper-
glycemia. Therefore, longer duration of diabetes may
contribute the prevalence of DR. Lower hemoglobin
levels were an independent predictor for the occurrence
and severity of DR in the previous studies [21,25]. There
is no clear evidence for the mechanism underlying the
association of anemia with DR. However, there are some
possible mechanisms of how anemia can adversely affect
medical outcomes. Hypoxia may alter angiogenesis, ca-
pillary permeability, vasomotor response and cell sur-
vival [26], which may contribute the adverse medical
outcomes including occurrence and progression of DR.
Our findings add value by supporting the use of the dur-
ation of diabetes and hemoglobin levels as additional
predictors for the presence of DR in patients with nor-
moalbuminuric type 2 DM.
Our study has some limitations. First, this study was a
cross-sectional study and the sample size was relatively
small. A larger prospective study may further elucidate
the occurrence and predictors of DR in patients with
normoalbuminuric type 2 DM. Second, this study is
single center study; therefore, the generalizability of
our results to other ethnic groups with type 2 DM
is uncertain.
Conclusions
DR is prevalent even in normoalbuminuric patients with
type 2 DM, and mild NPDR is the most common form.
The duration of diabetes, hemoglobin levels, and UAER
were independent predictors for the presence of DR, and
the UAER was the strongest predictor for DR. Our find-
ings suggest that even in patients with normoalbuminu-
ric type 2 DM, close monitoring for DR might be
needed for early detection of DR, especially if they have
a higher UAER, longer duration of diabetes, or lower
hemoglobin levels.
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